TUMOR-TARGETED SUPERANTIGENS - Fusion Protein Technologies for Biopharmaceuticals: Applications and Challenges - page 357

FIGURE 24.3 (A) Radioluminogram showing the localization of TTS/mAb molecules to the
targeted tumors (B16 melanoma transfected with EpCAM antigen). The corresponding tissue
section is shown above. (B) Tumor-selective recruitment of CD8 þ T cell (stained red) by C215Fab-
SEA to a B16-EpCAM melanoma (black) in a syngeneic mouse lung. (C) Inhibition of growth of
B16-EpCAM melanoma lung metastases after treatment with different TTS/mAb/SAg molecules.
(D) SADCC against 5T4-expressing Caki-2 cells mediated by 4-h incubation with 5T4Fab-SEA
(circle), anatumomab mafenatox (triangle), or naptumomab estafenatox (square) at the indicated
concentrations. (E) SDCC against MHC class II expressing Raji cells mediated by 4-h incubation
with 5T4Fab-SEA (circle), anatumomab mafenatox (triangle), or naptumomab estafenatox (square)
at the indicated concentrations. Source: Permission from Wolters Kluwer Health.